FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912691165> ?p ?o ?g. }

• W2912691165 abstract "HCT has been used for decades as a definitive therapy for patients with PIDs. These patients often enter HCT with significant comorbidities and disease sequelae and may have limited donor options if family members are also affected, so the ability to offer HCT to all who require it remains suboptimal. Twenty-nine children and adults with various underlying PIDs received a serotherapy-free, radiation-free reduced intensity conditioning platform designed with the goals of optimizing immune reconstitution, minimizing complications such as graft-versus-host disease (GVHD), and permitting use of alternative donors. Conditioning consisted of pentostatin, low-dose cyclophosphamide and 2 days of busulfan, and GVHD prophylaxis included post-transplantation cyclophosphamide, mycophenolate mofetil, and sirolimus. All received T cell replete bone marrow or peripheral blood stem cell allografts. Patient and donor characteristics are shown in Fig 1a. Neutrophil recovery occurred at median day +17 (range 14-42). With median follow-up of 14 months (range 3-33), graft-failure-free, steroid-refractory grade 3-4 GVHD-free survival was estimated at 82% at 1 year (Fig 2). Two deaths occurred in patients with HCT-CI scores of 6 (bacterial sepsis and invasive Aspergillosis, day +44) and 8 (presumed viral encephalitis, day +110). There were 3 graft failures (1 primary, with autologous recovery on day +14 and 2 secondary on day +34 and +159). Two patients were successfully retransplanted with eventual full donor chimerism, while the third's infection was sufficiently temporized by the first transplant to make an immediate retransplant not necessary.  The kinetics of donor chimerism differed between myeloid and lymphoid compartments. Most patients had complete donor myeloid chimerism by day +28 but a slower rise in donor CD3 chimerism (median 77% at day +28 to 94% at day +60) (Fig 3). GVHD rates have been low, with cumulative incidence of steroid-responsive grade 2-4 acute GVHD at 1 year of 14% (death and graft failure as competing risks) and no chronic GVHD to date.  HCT-related outcomes and complications are listed in Fig 1b. Of note, BK-associated hemorrhagic cystitis occurred at high rates, but serious viral complications were infrequent. Some degree of phenotype reversal is evident in all evaluable patients. All 10 patients with lymphoma or lymphoproliferative disorder are in remission, and, of 24 engrafted survivors, only two continue to require immunoglobulin replacement beyond 6 months post-HCT. Future directions include reducing the duration of post-HCT immunosuppression to hasten improved viral control and increasing pre-HCT lymphodepletion for selected patients at high risk for graft failure. Continued long term follow up is needed to better characterize phenotype reversal, graft durability, immune reconstitution and late toxicities of the platform." @default.
• W2912691165 created "2019-02-21" @default.
• W2912691165 creator A5005206087 @default.
• W2912691165 creator A5005602952 @default.
• W2912691165 creator A5019269444 @default.
• W2912691165 creator A5024634769 @default.
• W2912691165 creator A5027780462 @default.
• W2912691165 creator A5029163913 @default.
• W2912691165 creator A5030044268 @default.
• W2912691165 creator A5037782727 @default.
• W2912691165 creator A5039603636 @default.
• W2912691165 creator A5056552919 @default.
• W2912691165 creator A5058229432 @default.
• W2912691165 creator A5063867007 @default.
• W2912691165 creator A5066218992 @default.
• W2912691165 creator A5067851127 @default.
• W2912691165 creator A5074220802 @default.
• W2912691165 creator A5074932333 @default.
• W2912691165 creator A5078489211 @default.
• W2912691165 creator A5081737757 @default.
• W2912691165 creator A5082236040 @default.
• W2912691165 creator A5082458518 @default.
• W2912691165 creator A5084720533 @default.
• W2912691165 creator A5086602479 @default.
• W2912691165 creator A5089780095 @default.
• W2912691165 date "2019-03-01" @default.
• W2912691165 modified "2023-09-25" @default.
• W2912691165 title "Successful Allogeneic Hematopoietic Cell Transplantation (HCT) with Low Toxicity and Gvhd in a Heterogeneous Cohort of Primary Immunodeficiency (PID) Patients" @default.
• W2912691165 doi "https://doi.org/10.1016/j.bbmt.2018.12.118" @default.
• W2912691165 hasPublicationYear "2019" @default.
• W2912691165 type Work @default.
• W2912691165 sameAs 2912691165 @default.
• W2912691165 citedByCount "0" @default.
• W2912691165 crossrefType "journal-article" @default.
• W2912691165 hasAuthorship W2912691165A5005206087 @default.
• W2912691165 hasAuthorship W2912691165A5005602952 @default.
• W2912691165 hasAuthorship W2912691165A5019269444 @default.
• W2912691165 hasAuthorship W2912691165A5024634769 @default.
• W2912691165 hasAuthorship W2912691165A5027780462 @default.
• W2912691165 hasAuthorship W2912691165A5029163913 @default.
• W2912691165 hasAuthorship W2912691165A5030044268 @default.
• W2912691165 hasAuthorship W2912691165A5037782727 @default.
• W2912691165 hasAuthorship W2912691165A5039603636 @default.
• W2912691165 hasAuthorship W2912691165A5056552919 @default.
• W2912691165 hasAuthorship W2912691165A5058229432 @default.
• W2912691165 hasAuthorship W2912691165A5063867007 @default.
• W2912691165 hasAuthorship W2912691165A5066218992 @default.
• W2912691165 hasAuthorship W2912691165A5067851127 @default.
• W2912691165 hasAuthorship W2912691165A5074220802 @default.
• W2912691165 hasAuthorship W2912691165A5074932333 @default.
• W2912691165 hasAuthorship W2912691165A5078489211 @default.
• W2912691165 hasAuthorship W2912691165A5081737757 @default.
• W2912691165 hasAuthorship W2912691165A5082236040 @default.
• W2912691165 hasAuthorship W2912691165A5082458518 @default.
• W2912691165 hasAuthorship W2912691165A5084720533 @default.
• W2912691165 hasAuthorship W2912691165A5086602479 @default.
• W2912691165 hasAuthorship W2912691165A5089780095 @default.
• W2912691165 hasBestOaLocation W29126911651 @default.
• W2912691165 hasConcept C126322002 @default.
• W2912691165 hasConcept C141071460 @default.
• W2912691165 hasConcept C2776694085 @default.
• W2912691165 hasConcept C2776755627 @default.
• W2912691165 hasConcept C2777408962 @default.
• W2912691165 hasConcept C2779019163 @default.
• W2912691165 hasConcept C2779134260 @default.
• W2912691165 hasConcept C2779972918 @default.
• W2912691165 hasConcept C2780611847 @default.
• W2912691165 hasConcept C2911091166 @default.
• W2912691165 hasConcept C71924100 @default.
• W2912691165 hasConcept C90924648 @default.
• W2912691165 hasConceptScore W2912691165C126322002 @default.
• W2912691165 hasConceptScore W2912691165C141071460 @default.
• W2912691165 hasConceptScore W2912691165C2776694085 @default.
• W2912691165 hasConceptScore W2912691165C2776755627 @default.
• W2912691165 hasConceptScore W2912691165C2777408962 @default.
• W2912691165 hasConceptScore W2912691165C2779019163 @default.
• W2912691165 hasConceptScore W2912691165C2779134260 @default.
• W2912691165 hasConceptScore W2912691165C2779972918 @default.
• W2912691165 hasConceptScore W2912691165C2780611847 @default.
• W2912691165 hasConceptScore W2912691165C2911091166 @default.
• W2912691165 hasConceptScore W2912691165C71924100 @default.
• W2912691165 hasConceptScore W2912691165C90924648 @default.
• W2912691165 hasLocation W29126911651 @default.
• W2912691165 hasOpenAccess W2912691165 @default.
• W2912691165 hasPrimaryLocation W29126911651 @default.
• W2912691165 hasRelatedWork W2018352009 @default.
• W2912691165 hasRelatedWork W2122153475 @default.
• W2912691165 hasRelatedWork W2289576729 @default.
• W2912691165 hasRelatedWork W2887083318 @default.
• W2912691165 hasRelatedWork W2899271238 @default.
• W2912691165 hasRelatedWork W3099479999 @default.
• W2912691165 hasRelatedWork W4221008745 @default.
• W2912691165 hasRelatedWork W4244618670 @default.
• W2912691165 hasRelatedWork W4252754521 @default.
• W2912691165 hasRelatedWork W4283579591 @default.
• W2912691165 isParatext "false" @default.
• W2912691165 isRetracted "false" @default.
• W2912691165 magId "2912691165" @default.
• W2912691165 workType "article" @default.